Lilly Signs a ~$1.25B Research Collaboration with MiNA Therapeutics to Develop saRNA Therapies

Shota: MiNA to receive $25M as up front and is eligible to receive $245M as milestones for each of five potential targets along with royalties on product sales resulting from the collaboration Lilly will be responsible for the pre/ clinical development of candidates and will retain exclusive commercialization rights for any products emerges during the …

Lilly Signs a ~$1.25B Research Collaboration with MiNA Therapeutics to Develop saRNA Therapies Read More »